Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Francesco Merli, Stefano Luminari, Fiorella Ilariucci, Mario Petrini, Carlo Visco, Achille Ambrosetti, Caterina Stelitano, Francesco Caracciolo, Nicola di Renzo, Francesco Angrilli, Angelo M. Carella, Isabella Capodanno, Elisa Barbolini, Sara Galimberti, Massimo Federico

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P

Original languageEnglish
Pages (from-to)346-353
Number of pages8
JournalBritish Journal of Haematology
Volume156
Issue number3
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Mantle-Cell Lymphoma
Cytarabine
Methotrexate
Multicenter Studies
Therapeutics
Confidence Intervals
Survival
Disease-Free Survival
Rituximab
Stem Cells
Survival Rate
Transplants

Keywords

  • Chemotherapy
  • Clinical trials
  • Monoclonal antibodies
  • Non-Hodgkin lymphoma
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. / Merli, Francesco; Luminari, Stefano; Ilariucci, Fiorella; Petrini, Mario; Visco, Carlo; Ambrosetti, Achille; Stelitano, Caterina; Caracciolo, Francesco; di Renzo, Nicola; Angrilli, Francesco; Carella, Angelo M.; Capodanno, Isabella; Barbolini, Elisa; Galimberti, Sara; Federico, Massimo.

In: British Journal of Haematology, Vol. 156, No. 3, 02.2012, p. 346-353.

Research output: Contribution to journalArticle

Merli, Francesco ; Luminari, Stefano ; Ilariucci, Fiorella ; Petrini, Mario ; Visco, Carlo ; Ambrosetti, Achille ; Stelitano, Caterina ; Caracciolo, Francesco ; di Renzo, Nicola ; Angrilli, Francesco ; Carella, Angelo M. ; Capodanno, Isabella ; Barbolini, Elisa ; Galimberti, Sara ; Federico, Massimo. / Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. In: British Journal of Haematology. 2012 ; Vol. 156, No. 3. pp. 346-353.
@article{cee237bd464f4083b3ceb243fd79d4aa,
title = "Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi",
abstract = "This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60{\%}, 33{\%} and 7{\%} were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37{\%}) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83{\%} and 72{\%} respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73{\%} [95{\%} confidence interval (CI) 59-83{\%}], and 61{\%} (95{\%}CI 45-73{\%}) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89{\%}, 80{\%} and 24{\%} for L, I, and H groups respectively (P",
keywords = "Chemotherapy, Clinical trials, Monoclonal antibodies, Non-Hodgkin lymphoma, Prognostic factors",
author = "Francesco Merli and Stefano Luminari and Fiorella Ilariucci and Mario Petrini and Carlo Visco and Achille Ambrosetti and Caterina Stelitano and Francesco Caracciolo and {di Renzo}, Nicola and Francesco Angrilli and Carella, {Angelo M.} and Isabella Capodanno and Elisa Barbolini and Sara Galimberti and Massimo Federico",
year = "2012",
month = "2",
doi = "10.1111/j.1365-2141.2011.08958.x",
language = "English",
volume = "156",
pages = "346--353",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

AU - Merli, Francesco

AU - Luminari, Stefano

AU - Ilariucci, Fiorella

AU - Petrini, Mario

AU - Visco, Carlo

AU - Ambrosetti, Achille

AU - Stelitano, Caterina

AU - Caracciolo, Francesco

AU - di Renzo, Nicola

AU - Angrilli, Francesco

AU - Carella, Angelo M.

AU - Capodanno, Isabella

AU - Barbolini, Elisa

AU - Galimberti, Sara

AU - Federico, Massimo

PY - 2012/2

Y1 - 2012/2

N2 - This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P

AB - This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P

KW - Chemotherapy

KW - Clinical trials

KW - Monoclonal antibodies

KW - Non-Hodgkin lymphoma

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=84855796484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855796484&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08958.x

DO - 10.1111/j.1365-2141.2011.08958.x

M3 - Article

C2 - 22145911

AN - SCOPUS:84855796484

VL - 156

SP - 346

EP - 353

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -